THE PEPTIDE SOURCING PROBLEM: WHY QUALITY VARIES SO WILDLY

Most research peptides are manufactured using solid-phase peptide synthesis (SPPS), a method developed by Bruce Merrifield in the 1960s for which he received the 1984 Nobel Prize in Chemistry. In SPPS, amino acids are added sequentially to a solid support resin, building the peptide chain one residue at a time using protected chemistry. When complete, the peptide is cleaved from the resin and deprotected in a single step, yielding a crude peptide mixture.

Purification is where quality diverges dramatically. High-performance liquid chromatography (HPLC) is the standard purification method: the crude mixture is passed through a column under pressure, separating components by their interaction with the stationary phase. A well-run preparative HPLC purification can produce peptide material at 98–99%+ purity. A poorly run process — inadequate column separation, insufficient wash steps, wrong solvent gradients — produces material with significant impurity loads including deletion sequences, truncated peptides, and synthesis byproducts.

The final step, lyophilization (freeze-drying), converts the purified solution into the powder that's shipped to customers. If done correctly, the peptide is stable at room temperature for months. If done incorrectly — insufficient vacuum, temperature fluctuations, residual moisture — degradation begins during the process itself. Customers receive material that was already partially degraded before it left the manufacturer.

A Certificate of Analysis (COA) is a document reporting the results of analytical testing performed on a specific batch of product. A vendor-provided COA typically shows HPLC purity expressed as a percentage, often a mass spectrometry result confirming the compound's molecular weight, and sometimes additional parameters like water content or residual solvent levels.

The critical limitation: most vendor-provided COAs are generated by the vendor's own laboratory or by a contract lab with a commercial relationship with the vendor. This is fundamentally different from independent third-party testing. A vendor that generates its own COA is testing and reporting its own products — with all the motivated reasoning that relationship creates.

The meaningful distinction is between a vendor who commissions independent third-party mass spectrometry and HPLC from a laboratory with no commercial relationship to them, versus one who generates in-house COAs or uses a single affiliated lab. The former provides genuine analytical evidence. The latter provides documentation that may or may not accurately represent what's in the vial.

HPLC purity testing tells you what fraction of the UV-absorbing material in the sample elutes at the correct retention time for your target compound. An HPLC result of 98% purity means 98% of the absorbing material elutes at the expected time. It does not confirm that the material is actually your target peptide — a different compound with similar chromatographic properties could produce an identical result.

Mass spectrometry tells you the molecular weight of compounds in the sample and can provide structural information through fragmentation patterns. A positive MS result for BPC-157 means the sample contains material with the correct molecular weight (1419.56 Da). Combined with HPLC purity, this provides meaningful evidence that the sample is what it claims to be at the stated purity level.

Neither test addresses endotoxin. Bacterial lipopolysaccharide (endotoxin) contamination is invisible to both HPLC and mass spectrometry at the levels that cause biological harm in injected products. The pharmaceutical standard for endotoxin testing is the Limulus Amebocyte Lysate (LAL) assay. Almost no research peptide vendor performs or reports endotoxin testing. This is the most consequential gap in the testing consumers typically have access to.

Third-party testing from a laboratory without a vendor relationship is the baseline. Look for vendors who link to test results from independent labs — not PDFs they've generated themselves. A legitimate third-party lab report includes the sample submission date, analysis date, the lab's name and any accreditation, and results with sufficient raw data to be interpretable.

Sterile filtration is non-negotiable for any peptide intended for injection. The lyophilized powder should have been dissolved, sterile-filtered through a 0.22 micron membrane to remove bacteria and particulates, and then lyophilized. Vendors who specify this process in their manufacturing documentation are providing meaningful information. Vendors who don't address sterile filtration are providing a meaningful signal of a different kind.

Manufacturing location matters. Peptides synthesized in US-based or EU-based facilities operating under Good Manufacturing Practice (GMP) guidelines are subject to regulatory oversight that doesn't exist for facilities in other jurisdictions. The research peptide market has no mandatory GMP requirement, but vendors who voluntarily operate under GMP conditions are making a meaningful commitment that creates accountability.

Finally: price is not a proxy for quality in this market. The cost of good peptide synthesis and analytical testing is not substantially higher than cutting corners — raw material costs and equipment costs are similar regardless. Cheap products are cheap because something in the process was compromised, not because the manufacturer is passing savings along.